In summary, the results of these studies indicate that adding Daratumumab to the Venetoclax-based regimen is safe and can generate strong and long-lasting treatment responses; this treatment strategy may have synergistic effects, supporting further exploration of Venetoclax combined with anti-CD38 immunotherapy to treat R/R MM. Here, CD38 is linked to Miyoshi myopathy.